Key Development
Gilead Sciences and the Pan American Health Organization have established a new pathway to broaden access to twice-yearly injectable lenacapavir for HIV prevention across Latin America and the Caribbean. Under the agreement, 14 countries — including Brazil, Mexico, Argentina, Colombia, Chile and Peru — will be able to procure the medicine through PAHO’s Regional Revolving Funds, subject to national regulatory and implementation processes.
These countries sit outside Gilead’s existing voluntary-licensing arrangements. Another 24 countries in Latin America and the Caribbean are already covered through licensing agreements that form part of a wider global access framework spanning 120 countries. Gilead has also committed to advance a technology-transfer process in Brazil that could ultimately support local lenacapavir production.
The agreement arrives against a difficult epidemiological backdrop. Approximately 140,000 new HIV infections occur annually across Latin America and the Caribbean, while new infections increased 13% between 2010 and 2024. WHO recommended lenacapavir in 2025 as an additional HIV prevention option after clinical studies demonstrated close to 100% efficacy in preventing HIV acquisition.
Why It Matters
- Adherence could be fundamentally reshaped. Twice-yearly administration substantially reduces dosing frequency compared with daily oral PrEP and may benefit populations for whom continuous adherence is difficult.
- Pooled procurement strengthens public-sector purchasing power. PAHO’s Revolving Funds aggregate demand across participating countries and can support more reliable procurement under favorable conditions.
- Access is increasingly part of commercial strategy. Reuters identifies lenacapavir as an important growth asset for Gilead, with projected 2026 sales of around $1 billion. Expanding access therefore has both public-health and long-term market-development implications.
- Technology transfer could change the supplier relationship. If Brazil’s proposed program progresses, the model may gradually move beyond importing innovation toward building regional manufacturing capability.
Healthcare Insight Analysis
The strategic significance of the agreement is not simply that Gilead is opening another 14 markets. The company is effectively constructing a multi-layered access architecture around a single pharmaceutical innovation.
For lower-resource markets, Gilead is using royalty-free voluntary licensing alongside no-profit supply agreements with PEPFAR and the Global Fund, with commitments now intended to reach up to 3 million people through 2028. For middle-income markets outside the generic-licensing territory, the company is introducing a regional procurement mechanism through PAHO. Brazil potentially adds a third layer: local manufacturing through technology transfer.
This architecture addresses one of the pharmaceutical industry’s persistent challenges: clinical efficacy does not automatically translate into population-level health impact.
Lenacapavir illustrates the issue clearly. Twice-yearly dosing can potentially improve adherence and discretion, but reducing new infections at scale still requires regulatory authorization, clinical protocols, health-worker training, demand forecasting, budgets and patient monitoring. PAHO has therefore emphasized that national introduction will be progressive and dependent on health-system readiness.
For Gilead, the agreement also reinforces a broader strategy of building a franchise around lenacapavir rather than treating it as a single-product opportunity. The company is investigating the molecule across prevention and treatment settings. The FDA has already accepted an application for a once-weekly oral formulation of Yeztugo for PrEP, with an action date scheduled for February 2, 2027.
That makes access strategy commercially important as well. Broad early adoption can strengthen clinical familiarity, healthcare-system infrastructure and stakeholder relationships around a molecule that Gilead may ultimately deploy across multiple formulations and HIV indications.
Market Implications
For pharmaceutical companies, the agreement illustrates why market-access design increasingly needs to begin alongside clinical development, particularly for vaccines, anti-infectives and medicines with significant public-health value.
For governments and payers, regional pooled procurement offers a mechanism to consolidate volume, strengthen negotiating leverage and potentially accelerate the introduction of innovation into national programs.
For Latin American manufacturers, the Brazil technology-transfer process will be particularly important to watch. If successfully implemented, it could contribute to broader regional ambitions to build domestic capacity for sophisticated health technologies rather than relying exclusively on imported supply.
The larger message extends beyond HIV: in the next generation of pharmaceutical innovation, breakthrough science will be only the first step. Sustainable competitive advantage will increasingly depend on the ability to turn innovation into scalable, affordable and durable access.